US · Healthcare · Healthcare Plans
EPS came in at 0.34 against a street estimate of 0.28 — a beat of 21.4%.
Analysts rate Progyny Inc a buy (4 buy, 6 hold, 0 sell out of 10) with an average price target of $34.42.
CONFIDENT Q2 delivered record revenue, gross profit, and adjusted EBITDA with 180bp margin expansion. Strong selling season momentum with 1M+ life target on track. Summer seasonality noted but expected to normalize by fall. Q2 2026 No geographic breakdown provided. International expansion commentary limited to multinational employer strategies; not quantified. Analysts pressed summer seasonality, visibility into 2027 lives, and Select/channel materiality. Management clarified: seasonal softness typical but slightly elevated; good pipeline visibility; brownfield wins driven by cost inflation; Select/channels immaterial to 2027. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.50% |
| FMR Inc | 8.40% |
| Vanguard Portfolio Management, LLC | 6.84% |
| Vanguard Capital Management, LLC | 4.50% |
| State Street Corp | 3.98% |
| Ameriprise Financial Inc | 3.65% |
| Fort Washington Investment Advisors Inc | 3.29% |
| Morgan Stanley - Brokerage Accounts | 2.96% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 PROGYNY, INC. — Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue (Q2 2026): $350.5 million, up 5.3% from $332.9 million in Q2 2025 • Revenue (H1 | 2026-08-07 |
| Results announced · Q3 2026 PROGYNY, INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue: $350.5 million, up 5.3% YoY ($332.9 million in Q2 2025); excluding lost client | 2026-08-06 |
| Charter / bylaws change · Q2 2026 PROGYNY, INC. (PGNY) - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 21, 2026 with 72,003,873 shares represented (91.92% of shares ent | 2026-05-27 |
| Company announcement · Q2 2026 PROGYNY, INC. (PGNY) - 8-K FILING SUMMARY Date: May 26, 2026 --- HEADLINE NUMBERS • Board approved share repurchase program authorization of $200 m | 2026-05-26 |
| Quarterly report · Q1 2026 PROGYNY, INC. — Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue: $328.5 million (Q1 2026) vs. $324.0 million (Q1 2025) — up 1.4% yea | 2026-05-08 |
| Results announced · Q2 2026 PROGYNY, INC. — Q1 2026 FINANCIAL SUMMARY --- HEADLINE NUMBERS • Revenue: $328.5 million (up 1.4% YoY); excluding the large client who didn't renew | 2026-05-07 |
| Proxy statement · Q2 2026 PROGYNY, INC. – 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect 3 Class I Directors – Lloyd Dean, Kevin Gordon, and Cher | 2026-04-10 |
| Annual report FY2025 PROGYNY, INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization: Approximately $1.9 billion (as of June 30, 2025) • | 2026-02-27 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board approves $200 million share repurchase program Progyny, Inc. announced a $200 million share repurchase program approved by its Board of Directors. The company will buy back its own stock using cash on hand through open market purchases, | 2026-05-26 |
| Updated financial guidance for Q4 2025 and full year 2025 Progyny, Inc. issued an 8-K filing on January 12, 2026, announcing an update to its previously issued financial guidance for Q4 2025 and the full year 2025. The company released a press rele | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Progyny Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.